21 May 2013
Keywords: gilead, letairis, gets, fda, ok, who, class
Article | 25 June 2007
The US Food and Drug Aministration's approval of Letairis (ambrisentan) as a once-daily treatment for pulmonary arterial hypertension is,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 June 2007
20 May 2013
© 2013 thepharmaletter.com